VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
MedTech & Diagnostics

CareDx Executive Compensation (FY25)

CDNA · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
John Hanna
Median of the other named officers
$2,579,380
5 officers, excluding the chief executive
Latest say-on-pay support
=
June 11, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The CareDx brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 15, 2026
11 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
CareDx brief$500Get the executive brief
Velarion Intel, one year, every company
284 figures on this page: 277 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — John Hanna: $9,424,329 → $7,179,699 (23.8% lower)
CEO pay ratio: 71:1 → 48:1 (32.4% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is CareDx's chief executive and what were they paid?
John Hanna was paid $7,179,699 in total compensation as President and Chief Executive Officer for fiscal 2025. Hanna's total was 23.8% lower than the $9,424,329 reported for fiscal 2024.
What was CareDx's say-on-pay result?
The say-on-pay proposal drew 95.3% of votes cast including abstentions in favor at the meeting held June 11, 2026 for fiscal 2025.
Which companies are in CareDx's peer group?
The disclosed peer group names Adaptive Biotechnologies Corp., Alphatec Spine, Inc., AtriCure, Inc., Castle Biosciences, Inc. and Cerus Corporation, among others.
What is CareDx's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 48:1, against median employee compensation of $148,417.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
MBBS Reginald Seeto
Former Chief Executive Officer and President
◇—◇◇◇—◇◇
Alexander Johnson
Former President of Patient and Testing Services
◇—◇◇◇—◇◇
Abraham Ronai
Former Chief Administrative & Legal Officer and Secretary
◇—◇◇◇——◇
Abhishek Jain
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
MBBS Reginald Seeto
Former Chief Executive Officer and President
Departed during or after this year
◇—◇◇——◇◇
Abraham Ronai
Former Chief Administrative & Legal Officer and Secretary
Departed during or after this year
◇—◇◇——◇◇
Alexander Johnson
Former President of Patient and Testing Services
◇◇◇◇◇—◇◇
Abhishek Jain
Chief Financial Officer
◇◇◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Hanna
President and Chief Executive Officer
◇—◇◇◇—◇◇
Keith Kennedy
Chief Operating Officer
◇—◇◇◇—◇◇
Jessica Meng
Chief Commercial Officer
◇—◇◇◇—◇◇
Alexander Johnson
Former President of Patient and Testing Services
Departed during or after this year
◇—◇———◇◇
Abhishek Jain
Chief Financial Officer
◇◇◇—◇—◇◇
Jeffrey Novack
General Counsel and Secretary
◇◇◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Hanna
President and Chief Executive Officer
◇—◇—◇—◇◇
Keith Kennedy
Chief Operating Officer and Chief Financial Officer
◇—◇—◇—◇◇
Abhishek Jain
Former Chief Financial Officer
Departed during or after this year
◇—◇—◇—◇◇
Jessica Meng
Chief Commercial Officer
◇—◇—◇—◇◇
Jeffrey Novack
General Counsel and Secretary
◇—◇—◇—◇◇
Nathan Smith
Former Chief Financial Officer
Departed during or after this year
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Abhishek JainRSU◇——◇——◇
Jeffrey NovackRSU◇——◇——◇
Jessica MengRSU◇——◇——◇
John W. HannaRSU◇——◇——◇
Keith KennedyRSU◇——◇——◇
Nathan SmithRSU◇——◇——◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
John HannaOption◇—◇April 15, 2034
RSU◇◇——
RSU◇◇——
PSU◇◇——
Keith KennedyRSU◇◇——
Option◇—◇September 12, 2034
RSU◇◇——
PSU◇◇——
Abhishek JainRSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇February 1, 2033
Option◇—◇September 7, 2032
RSU◇◇——
RSU◇◇——
Option◇—◇May 26, 2032
RSU◇◇——
RSU◇◇——
Option◇—◇April 18, 2032
Option◇—◇May 6, 2032
Jessica MengRSU◇◇——
Option◇—◇September 12, 2034
RSU◇◇——
PSU◇◇——
Nathan SmithRSU◇◇——
PSU◇◇——
Jeffrey NovackRSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇August 6, 2032
Option◇—◇April 6, 2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Abhishek Jain
Former Chief Financial Officer · Change-in-control agreement
Severance base◇
Non-solicit period◇
Jeffrey Novack
General Counsel and Secretary · Change-in-control agreement
Severance base◇
Non-solicit period◇
Jessica Meng
Chief Commercial Officer · Change-in-control agreement
Severance base◇
Non-solicit period◇
John Hanna
President and Chief Executive Officer · Change-in-control agreement
Severance base◇
Non-solicit period◇
Keith Kennedy
Chief Operating Officer and Chief Financial Officer · Change-in-control agreement
Severance base◇
Non-solicit period◇
Nathan Smith
Former Chief Financial Officer · Change-in-control agreement
Severance base◇
Equity acceleration on change in control◇
Non-solicit period◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Suresh Gunasekaran
◇◇————◇
Michael D. Goldberg
Board chair
◇◇————◇
Christine M. Cournoyer
◇◇————◇
George W. Bickerstaff III
◇◇————◇
R. Bryan Riggsbee
◇◇————◇
Hannah A. Valantine, M.D
◇◇————◇
Arthur A. Torres
◇◇————◇
Fred E. Cohen, M.D., D. Phil
◇◇————◇
Peter Maag, Ph.D
◇◇————◇
William A. Hagstrom
◇—————◇
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Adaptive Biotechnologies Corp. ADPT
  • Alphatec Spine, Inc. ATEC
  • AtriCure, Inc. ATRC
  • Castle Biosciences, Inc. CSTL
  • Cerus Corporation CERS
  • Cytek Biosciences, Inc. CTKB
  • Fulgent Genetics, Inc. FLGT
  • Guardant Health, Inc. GH
  • iRhythm Technologies, Inc. IRTC
  • Maravai Lifesciences, Inc. MRVI
  • Myriad Genetics, Inc. MYGN
  • Natera, Inc. NTRA
  • NeoGenomics, Inc. NEO
  • Pacific Biosciences of California, PACB
  • Quanterix Corporation QTRX
  • Standard Bio Tools, Inc. symbol not shown
  • TransMedics Group TMDX
  • Twist Bioscience Corporation TWST
  • Veracyte, Inc. VCYT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 11, 2026=◇◇◇
2024June 12, 2025=◇◇◇
2023June 13, 2024=◇◇◇
2022June 15, 2023=◇◇◇
2021June 15, 2022=◇◇◇
2020June 15, 2021=◇◇◇
2019June 17, 2020=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- John Hanna (President and Chief Executive Officer), FY2025 total compensation $7,179,699 (base salary $693,269) [exec_comp, SEC accession 0001217234-26-000028, filed 2026-04-27]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when CareDx files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact CareDx disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where CareDx sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether CareDx's disclosed peer group is defensible, who names CareDx back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
284 figures on this page: 277 cited to the filing that reported them, 7 calculated from figures it prints.
277 cited to the filing
7 calculated from the filing

Documents cited

  1. 0001217234-26-000036
    Proposal 3: Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers.
  2. 0001217234-26-000028
    Director Compensation · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal Year-End · Pay Ratio Disclosure · and 1 more section
  3. 0001217234-26-000018
  4. 0001193125-25-139978
    Proposal No. 3 - To approve, on an advisory basis, the compensation of the Company’s named executive officers.
  5. 0001217234-25-000025
    Summary Compensation Table
  6. 0001217234-24-000071
  7. 0001217234-24-000042
    Summary Compensation Table
  8. 0001217234-23-000107
  9. 0001217234-22-000109
  10. 0001193125-21-193438
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001217234-20-000106
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “CareDx executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/CDNA (accessed 2026).
Short form: data: Velarion

The CareDx brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
11 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about CareDx and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers CareDx discloses

The companies named in CDNA's own disclosed peer group.

Adaptive Biotechnologies Corp.Alphatec Spine, Inc.AtriCure, Inc.Castle Biosciences, Inc.Cerus CorporationCytek Biosciences, Inc.Fulgent Genetics, Inc.Guardant Health, Inc.iRhythm Technologies, Inc.Maravai Lifesciences, Inc.Myriad Genetics, Inc.Natera, Inc.NeoGenomics, Inc.Pacific Biosciences of California,Quanterix CorporationTransMedics GroupTwist Bioscience CorporationVeracyte, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy